down arrow

Stryker Corp.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8636671013
USD
364.35
-1.6 (-0.44%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

362.46366.95

52 Week

329.16406.19
Valuation
Technical
Day's Volume

CASH

481.99 k

Shareholding (Mar 2025)

FII

18.97%

Held by 538 FIIs

DII

52.97%

Held by 63 DIIs

Promoter

0.18%

How big is Stryker Corp.?

22-Jun-2025

As of Jun 18, Stryker Corp. has a market capitalization of $142.69 billion, with net sales of $23.22 billion and a net profit of $2.86 billion over the latest four quarters.

As of Jun 18, Stryker Corp. has a market capitalization of 142,688.90 million, classifying it as a Large Cap company.<BR><BR>As of Jun 18, the company's net sales for the latest four quarters amount to 23,218.00 million, while the net profit for the same period is 2,859.00 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 20,634.00 million and total assets at 42,971.00 million.

Read More

What does Stryker Corp. do?

22-Jun-2025

Stryker Corporation is a medical technology company specializing in various medical technologies, with a market cap of approximately $142.69 billion and a net profit of $654 million as of March 2025. Key metrics include a P/E ratio of 34.00 and a dividend yield of 0.87%.

Overview: <BR>Stryker Corporation is a medical technology company that operates in the Pharmaceuticals & Biotechnology industry, specializing in a range of medical technologies.<BR><BR>Financial Snapshot: <BR>Net Sales: 5,866 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 654 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 142,688.90 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Dividend Yield: 0.87% <BR>Debt Equity: 0.69 <BR>Return on Equity: 20.53% <BR>Price to Book: 6.82<BR><BR>Contact Details: <BR>Address: 2825 Airview Blvd, PORTAGE MI: 49002-1802 <BR>Tel: 1 269 3892600 <BR>Website: https://www.stryker.com/

Read More

Who are in the management team of Stryker Corp.?

22-Jun-2025

As of March 2022, Stryker Corp.'s management team includes Chairman and CEO Kevin Lobo, Lead Independent Director Allan Golston, and Independent Directors Mary Brainerd, Srikant Datar, and Roch Doliveux, along with Director Giovanni Caforio. They are responsible for the company's strategic direction and governance.

As of March 2022, the management team of Stryker Corp. includes the following members:<BR><BR>- Mr. Kevin Lobo, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Allan Golston, who is the Lead Independent Director.<BR>- Dr. Giovanni Caforio, who is a Director.<BR>- Ms. Mary Brainerd, who serves as an Independent Director.<BR>- Dr. Srikant Datar, who is also an Independent Director.<BR>- Dr. Roch Doliveux, who is another Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and governance.

Read More

Is Stryker Corp. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Stryker Corp. is in a mildly bearish trend, indicated by bearish MACD readings and underperformance against the S&P 500, despite some daily moving averages showing mild bullishness.

As of 12 September 2025, the technical trend for Stryker Corp. has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by weekly and monthly MACD readings, both indicating a bearish outlook. The KST and Dow Theory also reflect a mildly bearish trend on both time frames. Although the daily moving averages show a mildly bullish signal, this is overshadowed by the overall bearish indicators. The stock has underperformed compared to the S&P 500 over the past week and month, with returns of -2.82% and -0.99% respectively, while the S&P 500 gained 1.05% and 2.33%.

Read More

Is Stryker Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Stryker Corp. is considered overvalued with a P/E ratio of 34, an EV to EBITDA ratio of 25.94, and a PEG ratio of 1.86, indicating it trades at a premium compared to peers like Abbott Laboratories and Medtronic, while also underperforming the S&P 500.

As of 17 October 2025, the valuation grade for Stryker Corp. has moved from very expensive to expensive, indicating a slight improvement but still suggesting that the stock is overvalued. The company is currently assessed as overvalued based on its P/E ratio of 34, which is significantly higher than the industry average, and an EV to EBITDA ratio of 25.94, also above typical industry levels. Additionally, the PEG ratio stands at 1.86, suggesting that the stock may not be justified at its current price given its growth prospects.<BR><BR>In comparison to its peers, Abbott Laboratories has a P/E of 18.36, while Medtronic Plc shows a P/E of 21.47, both indicating that Stryker is trading at a premium relative to these companies. Notably, Stryker's recent stock performance has lagged behind the S&P 500, with a year-to-date return of 3.99% compared to the S&P 500's 13.30%, and a three-year return of 73.64% versus 81.19% for the index. This underperformance reinforces the notion that Stryker Corp. is overvalued in the current market environment.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company has very low debt and has enough cash to service the debt requirements

 
2

Flat results in Jun 25

3

With ROCE of 14.53%, it has a very expensive valuation with a 4.55 Enterprise value to Capital Employed

4

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 150,289 Million (Large Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.84%

stock-summary
Debt Equity

0.67

stock-summary
Return on Equity

21.38%

stock-summary
Price to Book

7.09

Revenue and Profits:
Net Sales:
6,022 Million
(Quarterly Results - Jun 2025)
Net Profit:
884 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.61%
0%
-7.61%
6 Months
-4.76%
0%
-4.76%
1 Year
-6.52%
0%
-6.52%
2 Years
25.23%
0%
25.23%
3 Years
49.87%
0%
49.87%
4 Years
47.59%
0%
47.59%
5 Years
52.07%
0%
52.07%

Stryker Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Stryker Corp. Hits Day Low of $355.75 Amid Price Pressure

Stryker Corp. Hits Day Low of $355.75 Amid Price Pressure

Stryker Corp. faced a significant stock price decline today, marking a challenging trading session. Over the past week and month, the company has experienced notable decreases, contrasting with modest gains in the S&P 500. Despite these challenges, Stryker maintains a strong financial position and robust institutional holdings.

Read More
Stryker Corp. Experiences Valuation Adjustment Amidst Competitive Market Landscape

Stryker Corp. Experiences Valuation Adjustment Amidst Competitive Market Landscape

Stryker Corp. has recently adjusted its valuation, with a current P/E ratio of 34 and a Price to Book Value of 7.01. Key financial metrics include an EV to EBIT of 31.29 and a PEG ratio of 1.86, reflecting strong operational efficiency and competitive positioning within the industry.

Read More

Is Stryker Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Stryker Corp. has moved from very expensive to expensive, indicating a slight improvement but still suggesting that the stock is overvalued. The company is currently assessed as overvalued based on its P/E ratio of 34, which is significantly higher than the industry average, and an EV to EBITDA ratio of 25.94, also above typical industry levels. Additionally, the PEG ratio stands at 1.86, suggesting that the stock may not be justified at its current price given its growth prospects. In comparison to its peers, Abbott Laboratories has a P/E of 18.36, while Medtronic Plc shows a P/E of 21.47, both indicating that Stryker is trading at a premium relative to these companies. Notably, Stryker's recent stock performance has lagged behind the S&P 500, with a year-to-date return of 3.99% compared to the S&P 500's 13.30%, and a three-year return of 73.64% versus 81.19%...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.10%
EBIT Growth (5y)
14.82%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
2.44
Net Debt to Equity (avg)
0.69
Sales to Capital Employed (avg)
0.64
Tax Ratio
14.22%
Dividend Payout Ratio
41.74%
Pledged Shares
0
Institutional Holding
81.62%
ROCE (avg)
13.69%
ROE (avg)
18.82%
Valuation key factors
Factor
Value
P/E Ratio
34
Industry P/E
Price to Book Value
7.01
EV to EBIT
31.29
EV to EBITDA
25.94
EV to Capital Employed
4.55
EV to Sales
6.94
PEG Ratio
1.86
Dividend Yield
0.85%
ROCE (Latest)
14.53%
ROE (Latest)
20.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 209 Schemes (27.87%)

Foreign Institutions

Held by 538 Foreign Institutions (18.97%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 11.07% vs 8.53% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 7.15% vs 11.79% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,022.00",
          "val2": "5,422.00",
          "chgp": "11.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,657.00",
          "val2": "1,416.00",
          "chgp": "17.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "159.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-231.00",
          "val2": "-89.00",
          "chgp": "-159.55%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "884.00",
          "val2": "825.00",
          "chgp": "7.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "226.00%",
          "val2": "213.60%",
          "chgp": "1.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.23% vs 11.11% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -5.43% vs 34.22% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "22,595.00",
          "val2": "20,498.00",
          "chgp": "10.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6,111.00",
          "val2": "5,309.00",
          "chgp": "15.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "396.00",
          "val2": "356.00",
          "chgp": "11.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,297.00",
          "val2": "-334.00",
          "chgp": "-288.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2,993.00",
          "val2": "3,165.00",
          "chgp": "-5.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "224.00%",
          "val2": "208.80%",
          "chgp": "1.52%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
6,022.00
5,422.00
11.07%
Operating Profit (PBDIT) excl Other Income
1,657.00
1,416.00
17.02%
Interest
159.00
0.00
Exceptional Items
-231.00
-89.00
-159.55%
Consolidate Net Profit
884.00
825.00
7.15%
Operating Profit Margin (Excl OI)
226.00%
213.60%
1.24%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 11.07% vs 8.53% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 7.15% vs 11.79% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
22,595.00
20,498.00
10.23%
Operating Profit (PBDIT) excl Other Income
6,111.00
5,309.00
15.11%
Interest
396.00
356.00
11.24%
Exceptional Items
-1,297.00
-334.00
-288.32%
Consolidate Net Profit
2,993.00
3,165.00
-5.43%
Operating Profit Margin (Excl OI)
224.00%
208.80%
1.52%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 10.23% vs 11.11% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -5.43% vs 34.22% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Stryker Corp. stock-summary
stock-summary
Stryker Corp.
Pharmaceuticals & Biotechnology
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. Its segments include Orthopaedics, MedSurg, Neurotechnology and Spine. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. Its products include implants, which are used in joint replacement and trauma surgeries, and other products. It offers musculoskeletal care and sensor technology for total joint replacement.
Company Coordinates stock-summary
Company Details
2825 Airview Blvd , PORTAGE MI : 49002-1802
stock-summary
Tel: 1 269 3892600
stock-summary
https://www.stryker.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."